Strand Life Sciences, a
global genomic profiling company aimed at empowering personalized cancer care and genetic
testing for inherited diseases, announced that its Next-Generation Sequencing
(NGS) laboratory, the Strand Center for Genomics & Personalized Medicine,
located at Bangalore, has recently received certificates of accreditation from
the College of American Pathologists (CAP), and the National Accreditation
Board for Testing and Calibration Laboratories (NABL), respectively. With
these accreditations, Strand’s pioneering NGS laboratory is the first and only
facility in India to receive both prestigious recognitions, signifying NGS
testing at the highest quality standards in the country and neighboring
geographical regions.
The CAP
laboratory accreditation program is recognized by the U.S. federal government
as equal-to or more-stringent-than the government’s own laboratory inspection
programs. Similarly, the accreditation by NABL, the sole government-authorized laboratory
accreditation body in India, is in accordance with ISO
15189:2012 standards. The accrediting processes by both organizations are
designed to ensure that laboratories comply with the highest standards, and
adhere to rigorous criteria for quality assurance. During the CAP accreditation process,
inspectors examine the laboratory's quality system, quality control protocols
and records for the preceding two years. Both programs pay very close attention
to staff qualification, equipment, safety programs, and overall management of
clinical laboratories.
This
recognition by CAP and NABL accredits three of the most popular tests offered
by the Strand Center laboratory. First, the StrandAdvantage 48-gene Test, used
by medical oncologists to profile cancer patients for somatic mutations and
personalize treatment by selecting targeted therapies. Second, the Strand Germline
Cancer Test, an 86-gene hereditary cancer test to estimate inherited cancer
risk, enabling early detection and prevention. Third, the Strand Rare
Diseases Test, covering more than 500 genes and 400 rare inherited diseases,
used for confirmation of diagnosis and carrier testing in couples.
Dr. Vijay
Chandru, PhD, Executive Chairman, Strand Life Sciences, stated, “We are extremely proud to receive CAP
and NABL accreditations. Receiving these accreditations is a major
accomplishment, because it reaffirms our commitment to providing the highest
quality of diagnostic testing and services to hospitals, physicians, and most
importantly patients across the country. It is Strand’s goal to bring
genomics-based precision medicine to routine clinical practice; hence the
accreditations serve as an important milestone in that direction”. Dr. Chandru
added, “We believe Strand’s NGS laboratory is the first and only CAP and NABL
accredited laboratory in India. As the regional leader in this advanced field
of multi-gene testing in genomic medicine, it is important for us to set the
highest laboratory standards."
“It is
imperative that physicians feel confident while sending patient samples for
specialized and esoteric testing, such as NGS for cancer and rare inherited disorders.
These diagnostic tests require advanced laboratories and expert personnel to
analyze and interpret complex genetic information. Laboratories whose quality
systems have been accredited by organizations such as CAP and NABL will give
physicians much needed confidence to refer precious patient samples” said Dr. Nanda Rajaneesh, MBBS, MS,
MRCS, FAMS, Consultant Surgical Oncologist, Apollo Spectra Hospitals,
Bangalore.